Francesco Negro
#129,126
Most Influential Person Now
Researcher
Francesco Negro's AcademicInfluence.com Rankings
Francesco Negrocomputer-science Degrees
Computer Science
#5596
World Rank
#5910
Historical Rank
Computational Linguistics
#821
World Rank
#834
Historical Rank
Machine Learning
#1547
World Rank
#1569
Historical Rank
Artificial Intelligence
#1778
World Rank
#1810
Historical Rank
Download Badge
Computer Science
Francesco Negro's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Francesco Negro Influential?
(Suggest an Edit or Addition)Francesco Negro's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2017) (1601)
- Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. (2010) (1216)
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (2018) (1034)
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
- Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. (2006) (784)
- Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. (2000) (594)
- Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. (2006) (560)
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt (2011) (517)
- EASL recommendations on treatment of hepatitis C - Final update of the series. (2020) (497)
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014) (477)
- Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates (2019) (452)
- Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States (2012) (447)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. (2018) (397)
- STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (379)
- EASL Clinical Practice Guidelines on hepatitis E virus infection. (2018) (329)
- Extrahepatic morbidity and mortality of chronic hepatitis C. (2015) (313)
- Steatosis affects chronic hepatitis C progression in a genotype specific way (2004) (303)
- Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) (295)
- Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. (2009) (286)
- Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress (2007) (273)
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
- Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. (2006) (230)
- The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype‐specific mechanisms (2007) (228)
- Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. (2001) (225)
- IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection (2006) (225)
- Strategies to manage hepatitis C virus (HCV) disease burden (2014) (218)
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. (2017) (216)
- IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction (2013) (214)
- Human herpes virus‐6 increases HIV‐1 expression in co‐infected T cells via nuclear factors binding to the HIV‐1 enhancer. (1989) (211)
- Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. (1998) (200)
- Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. (2008) (194)
- An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. (2005) (187)
- The hepatitis delta virus: Replication and pathogenesis. (2016) (185)
- IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study (2011) (184)
- Hepatitis C virus and type 2 diabetes. (2009) (174)
- Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data (2009) (173)
- Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms (2011) (172)
- The interaction of metabolic factors with HCV infection: does it matter? (2012) (165)
- Mechanisms and significance of liver steatosis in hepatitis C virus infection. (2006) (164)
- International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. (2005) (162)
- Abnormalities of lipid metabolism in hepatitis C virus infection (2010) (158)
- Trends and projections of hepatitis C virus epidemiology in Latin America (2011) (156)
- Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta‐analysis (2011) (155)
- Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. (2012) (155)
- IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes (2012) (153)
- Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology. (1992) (151)
- APACHE II score does not predict multiple organ failure or mortality in postoperative surgical patients. (1990) (150)
- Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. (2014) (146)
- The global health burden of hepatitis C virus infection (2011) (140)
- Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. (2011) (140)
- Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C (2010) (138)
- Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. (1983) (137)
- Hepatitis D virus: an update (2011) (130)
- Is genotype 3 of the hepatitis C virus the new villain? (2014) (125)
- Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. (2002) (123)
- Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes (2014) (123)
- Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. (2010) (114)
- Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. (2011) (114)
- IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. (2011) (114)
- Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. (2008) (110)
- Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. (2001) (105)
- Extranodal lymphomas associated with hepatitis C virus infection. (1998) (104)
- Nosocomial outbreak of multiple bloodborne viral infections. (2001) (99)
- Molecular evidence that the hepatitis C virus replicates in the oral mucosa. (2001) (97)
- Impact of common risk factors of fibrosis progression in chronic hepatitis C (2014) (96)
- Hepatitis delta virus inhibits alpha interferon signaling (2009) (95)
- Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. (2008) (90)
- Monocyte chemoattractant protein‐1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes (2008) (87)
- Epidemiology of hepatitis C in Europe. (2014) (86)
- Galectin‐3, a marker of well‐differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia (2002) (85)
- Peroxisome proliferator‐activated receptor‐α and ‐γ mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection (2006) (85)
- Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. (2001) (84)
- Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C (2005) (84)
- Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients (2008) (83)
- Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection (2007) (83)
- LIVER TRANSPLANTATION IN HEPATITIS DELTA VIRUS DISEASE (1987) (81)
- Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). (2007) (79)
- Hepatitis D virus coinfection and superinfection. (2014) (78)
- Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid (2000) (76)
- HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). (2007) (76)
- Down‐regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets (2011) (75)
- Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. (2013) (75)
- A review on hepatitis D: From virology to new therapies (2019) (75)
- Antigenic relevance of F protein in chronic hepatitis C virus infection (2004) (75)
- Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? (2020) (73)
- Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets (2016) (71)
- Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. (2006) (71)
- Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C (2009) (70)
- Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index (2014) (69)
- Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. (2020) (66)
- Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C (1995) (65)
- Preoperative parenteral nutrition in the high risk surgical patient. (1988) (65)
- Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3 (2001) (65)
- Chronic HDV (hepatitis delta virus) hepatitis. Intrahepatic expression of delta antigen, histologic activity and outcome of liver disease. (1988) (64)
- Natural history of NASH and HCC (2020) (63)
- Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development (2013) (62)
- A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C (2012) (62)
- Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks (1989) (61)
- Evidence for replication of hepatitis delta virus RNA in hepatocyte nuclei after in vivo infection. (1988) (61)
- Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. (1998) (60)
- Insulin resistance and HCV: will new knowledge modify clinical management? (2006) (60)
- Correction: Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes (2014) (59)
- The negative impact of HBV/HCV coinfection on cirrhosis and its consequences (2017) (59)
- Hepatitis B virus DNA (HBV-DNA) in anti-HBe positive sera. (2008) (56)
- The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. (2010) (55)
- Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data (2011) (55)
- The natural history of chronic delta hepatitis. (1987) (54)
- Detection of HBV‐DNA by in situ hybridization using a biotin‐labeled probe (1985) (54)
- Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity (2006) (54)
- Impaired hepatic mitochondrial oxidation using the 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. (2003) (51)
- Current understanding of insulin resistance in hepatitis C (2011) (51)
- Adverse effects of drugs in the treatment of viral hepatitis. (2010) (50)
- Hepatitis C Virus Infection: Molecular Pathways to Steatosis, Insulin Resistance and Oxidative Stress (2009) (50)
- Chronic hepatitis D virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV. (1988) (48)
- Hepatitis C virus and liver steatosis: Is it the virus? Yes it is, but not always (2002) (48)
- Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection (2008) (47)
- Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. (2005) (47)
- Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon‐alpha and ribavirin therapy (2012) (47)
- Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review (2016) (46)
- Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. (2016) (46)
- A combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features. (2008) (46)
- Ribavirin/interferon-α sequential treatment of recurrent hepatitis C after liver transplantation (2004) (46)
- Mixed medullary-follicular carcinoma of the thyroid. A morphological, immunohistochemical and in situ hybridization analysis of 11 cases. (1997) (45)
- In situ detection of hepatitis C virus--a critical appraisal. (1996) (45)
- Hepatitis C Virus-Induced Steatosis: An Overview (2010) (44)
- Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C (2015) (44)
- IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4 (2013) (44)
- Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ⇑ (2015) (43)
- Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. (1994) (41)
- Hepatitis E virus: a zoonosis adapting to humans. (2010) (41)
- Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. (2020) (41)
- Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner (2019) (41)
- Deficient Natural Killer Cell NKp30‐Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma (2019) (41)
- PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. (2013) (40)
- Mixed medullary-follicular carcinoma of the thyroid (1997) (40)
- The impact of hepatitis C virus outside the liver: Evidence from Asia (2017) (40)
- Clinical and immunological features of hepatitis C treatment‐associated dermatitis in 36 prospective cases (2005) (39)
- Steatosis and insulin resistance in response to treatment of chronic hepatitis C (2012) (39)
- NAFLD and MAFLD as emerging causes of HCC: A populational study (2021) (38)
- Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study (2012) (37)
- Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance (2017) (36)
- Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. (2013) (35)
- Hepatitis C Virus, the E2 Envelope Protein, and α-Interferon Resistance (2000) (35)
- Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland (2015) (34)
- The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients (2011) (34)
- Sepsis and exogenous lipid modulation. (1988) (34)
- A systematic review and meta‐analysis of HCV clearance (2017) (32)
- Hepatitis C virus and glucose and lipid metabolism. (2008) (32)
- Gene expression profile of Huh‐7 cells expressing hepatitis C virus genotype 1b or 3a core proteins (2009) (32)
- Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. (2016) (32)
- Devil hepatitis D: an orphan disease or largely underdiagnosed? (2018) (31)
- Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (2013) (31)
- Preoperative parenteral nutrition of malnourished surgical patients. (1988) (31)
- Chronic hepatitis E in the immunosuppressed: a new source of trouble? (2009) (31)
- Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C (2007) (31)
- Thyroglobulin mRNA expression helps to distinguish anaplastic carcinoma from angiosarcoma of the thyroid (2000) (31)
- HCV infection and metabolic syndrome: which is the chicken and which is the egg? (2012) (30)
- Mechanisms of hepatitis C virus-related insulin resistance. (2011) (29)
- Drug Pricing Evolution in Hepatitis C (2016) (29)
- Hepatitis delta virus infection. (1990) (29)
- Basis of hepatitis delta virus disease? (1989) (28)
- Hepatitis C virus and liver steatosis: when fat is not beautiful. (2004) (28)
- IMMUNOLOGICAL AND VIROLOGICAL EFFECTS OF RIBAVIRIN IN HEPATITIS C AFTER LIVER TRANSPLANTATION1 (2002) (28)
- Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e. (2014) (28)
- Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. (1989) (28)
- Reappearance of hepatitis D virus (HDV) replication in chronic hepatitis B virus carrier chimpanzees rechallenged with HDV. (1989) (27)
- The impact of obesity and metabolic syndrome on chronic hepatitis C. (2014) (27)
- HCV 3a Core Protein Increases Lipid Droplet Cholesteryl Ester Content via a Mechanism Dependent on Sphingolipid Biosynthesis (2014) (27)
- Cutaneous side‐effects of treatment of chronic hepatitis C by interferon alfa and ribavirin (2003) (26)
- A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3. (2000) (25)
- Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
- Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: Comparison between different genotypes and core protein sequence analysis (2011) (25)
- The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease (2018) (25)
- Activation of the oncogenic miR‐21‐5p promotes HCV replication and steatosis induced by the viral core 3a protein (2019) (24)
- IL 28 B , HLA-C , and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort : A Cross-Sectional Study (2011) (24)
- Pegylated interferon‐alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation (2009) (24)
- Intrahepatic markers of hepatitis delta virus infection: A study by in Situ hybridization (1989) (24)
- IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5 (2012) (23)
- The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection (2014) (23)
- Hepatitis C virus: the viral way to fatty liver. (2007) (23)
- Lack of evidence for ribavirin‐induced bone loss (2002) (23)
- Hepatocellular adenoma and polycystic ovary syndrome (2003) (22)
- Albumin gene expression in liver tumors: diagnostic interest in fine needle aspiration biopsies. (1994) (22)
- Cardiovascular Manifestations of Hepatitis C Virus. (2017) (22)
- Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. (1994) (21)
- Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. (2008) (21)
- Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. (2004) (21)
- Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C (2012) (21)
- Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries (2018) (21)
- Securing sustainable funding for viral hepatitis elimination plans (2019) (21)
- Hepatitis C in 2013: HCV causes systemic disorders that can be cured (2014) (20)
- Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients (2019) (20)
- Microsomal autoantibodies in chronic infections with HBsAg associated delta agent (1983) (20)
- Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study (2009) (20)
- Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis. (2001) (20)
- Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes (2015) (19)
- CASE REPORT: Acute Valproate-Associated Microvesicular Steatosis: Could the [13C]Methionine Breath Test Be Useful to Assess Liver Mitochondrial Function? (2001) (19)
- Hepatitis C virus infection and disease. Diagnostic problems. (1993) (19)
- Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland’s largest pre-trial prison (2018) (18)
- Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance. (2000) (18)
- Severe anemia following combined α-interferon/ribavirin therapy of chronic hepatitis C (1998) (18)
- Ribavirin/interferon‐α sequential treatment of recurrent hepatitis C after liver transplantation (2004) (18)
- In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. (2006) (18)
- Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection. (2015) (18)
- Lack of in vivo blockade of Fas‐ and TNFR1‐mediated hepatocyte apoptosis by the hepatitis C virus (2002) (17)
- The paradox of Epstein-Barr virus-associated hepatitis. (2006) (17)
- The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. (2010) (17)
- Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon‐α and ribavirin in chronic hepatitis C virus patients (2014) (17)
- Detection of hepatitis delta virus RNA by a nonradioactive in situ hybridization procedure. (1992) (17)
- Acute and Chronic Hepatitis: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition (2004) (17)
- DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin (2002) (17)
- Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha. (1997) (16)
- 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION (2010) (16)
- Effect of antiviral therapy on circulating cytokeratin‐18 fragments in patients with chronic hepatitis C (2010) (16)
- Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials (2019) (16)
- Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. (2015) (16)
- Does the hepatitis C virus replicate in cells of the hematopoietic lineage? (1998) (16)
- Presacral epidermoid cyst. A case report. (2006) (16)
- Primary hepatic diffuse large B-cell lymphoma in a patient with chronic hepatitis C. (1999) (16)
- Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. (2012) (16)
- STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in Rosiglitazone-treated mice (2013) (16)
- Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection (2012) (15)
- Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells. (2006) (15)
- Residual risk of liver disease after hepatitis C virus eradication. (2020) (15)
- Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. (2019) (15)
- Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost‐effectiveness analysis (2018) (15)
- Pathobiology of hepatitis delta virus. (1993) (15)
- Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg‐interferon alpha‐2b plus ribavarin (2005) (15)
- Gastric cancer in the elderly. (2001) (15)
- Validity of serum albumin, total lymphocyte count, and weight loss in predicting postoperative nutrition-associated complications. (1990) (14)
- Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C. (1998) (14)
- Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (14)
- Trends in hepatitis C‐related mortality in Switzerland (2018) (14)
- A polymerase-chain reaction-based assay for serum HDV RNA. (1991) (14)
- Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. (1994) (14)
- Peroxisome Proliferator-Activated Receptors and Hepatitis C Virus-Induced Insulin Resistance (2009) (13)
- The fluctuations of hepatitis C virus RNA and IgM anti‐HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon (1995) (13)
- Hepatitis delta virus, a model of liver cell pathology. (1991) (13)
- Hepatitis delta virus heterogeneity: a study by immunofluorescence. (1991) (13)
- Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. (2012) (13)
- Preoperative Parenteral Nutrition in the High Risk Surgical Patient (1989) (13)
- Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis (2019) (13)
- Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers. (2009) (13)
- Hepatitis delta virus: From structure to disease expression (1992) (12)
- Preoperative parenteral nutrition in malnourished high-risk surgical patients. (1990) (12)
- Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? (2018) (12)
- MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective (2021) (12)
- Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease (2018) (11)
- HCV genotype 3 and squamous cell carcinoma antigen (SCCA)‐IgM are independently associated with histological features of NASH in HCV‐infected patients (2015) (11)
- Molecular markers of whv and hdv in single cells (1987) (11)
- Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. (2019) (11)
- How should we treat recurrent hepatitis C after liver transplantation? (2005) (11)
- Treatment of chronic hepatitis C with α-interferon plus ofloxacin in patients not responding to α-interferon alone (1998) (11)
- Colorectal cancer: obstruction is an independent negative prognostic factor after radical resection. (2002) (11)
- The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1–infected patients treated with Peg‐IFN‐alfa‐2a and ribavirin (2012) (11)
- Drugs improving insulin resistance for non‐alcoholic fatty liver disease and/or non‐alcoholic steatohepatitis (2013) (11)
- BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease (2016) (11)
- Estimating HCV disease burden—volume 4 (editorial) (2017) (10)
- Experimental hepatitis delta virus infection in the animal model. (1991) (10)
- Multiple Organ Failure Syndrome: Patterns and Effect of Current Therapy (1990) (10)
- Papillary carcinoma in amyloid goitre. (2000) (10)
- High-titered anti-HBs fresh frozen plasma for immunoprophylaxis against hepatitis B virus recurrence after liver transplantation. (1997) (10)
- Management of chronic hepatitis B: an update. (2011) (10)
- Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting. (2019) (10)
- P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER (2015) (9)
- Enterocutaneous fistulas: effect of nutritional management and surgery. (1989) (9)
- [Occasional detection of "struma ovarii" in a patient with thyroid carcinoma]. (1991) (9)
- Long-term hepatitis E viral load kinetics in an immunocompromised patient treated with ribavirin. (2014) (9)
- Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. (2019) (9)
- the Swiss Hepatitis C Cohort Study Group (2011) (9)
- [Hepatitis C virus infection. Overview. SEVHEP (Swiss Experts on Viral Hepatitis)]. (2000) (9)
- Nutritional Monitoring in the lCU: Rational and Practical Application (1988) (9)
- Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein (2016) (9)
- Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations (2016) (9)
- Hepatitis B virus subtypes and lamivudine resistance (2001) (8)
- Role of seipin in lipid droplet morphology and hepatitis C virus life cycle. (2013) (8)
- Towards a vaccine for the prevention of hepatitis delta virus superinfection in HBV carriers. (1993) (8)
- Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy. (2008) (8)
- Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. (1997) (8)
- Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. (2016) (8)
- Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. (2019) (8)
- Active HBV replication in HBsAg carriers with chronic Delta infection (1985) (8)
- HDV Pathogenesis: Unravelling Ariadne’s Thread (2021) (8)
- Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non‐neoplastic liver tissues (1997) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- SARS-CoV-2 and liver damage: a possible pathogenetic link. (2020) (8)
- A buyers' club to improve access to hepatitis C treatment for vulnerable populations. (2018) (8)
- Detection of hepatitis C virus RNA in liver tissue: an overview. (1998) (8)
- Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy (2021) (8)
- Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection. (1996) (7)
- Interferon-α (IFN) induction dosing and ribavirin (R) in IFN non-responders (NR) with chronic hepatitis C (CHC): Interim analysis of an ongoing study (SASL 10) (2000) (7)
- Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay (1995) (7)
- [New aspects of HEV infection]. (2008) (7)
- Mechanism of action of ribavirin in treatment of recurrent hepatitis c after liver transplant (2000) (7)
- Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. (2010) (7)
- Oral lichen planus pathogenesis: A role for the HCV‐specific cellular immune response (2002) (7)
- Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study. (1997) (7)
- Are there any subgenomic forms of hepatitis C virus RNA in the liver? (2001) (7)
- Does telaprevir possess a direct antidiabetic effect? (2014) (6)
- Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America (2018) (6)
- In situ hybridization in viral hepatitis. (1992) (6)
- Nucleic acid polymers: much-needed hope for hepatitis D? (2017) (6)
- Nutritional monitoring in the ICU: rational and practical application. (1988) (6)
- Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. (1998) (6)
- Safe switch to β-interferon treatment of chronic hepatitis C after α-interferon-induced autoimmune thrombocytopenia (1996) (6)
- Detection of cytomegalovirus by in situ hybridization using a digoxigenin-tailed oligonucleotide. (2008) (6)
- Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person‐centred approach (2016) (5)
- Expanded benefits of curing the extrahepatic manifestations of HCV infection (2018) (5)
- Hepatitis C virus genotype 1 associated with massive steatosis of the liver and hypo-β-lipoproteinemia (2004) (5)
- Hepatitis C virus and lymphomagenesis: Another piece of evidence (2002) (5)
- Interferon-induced "lupoid" thrombocytopenia in chronic hepatitis C. (1996) (5)
- Immunoglobulin M anti-hepatitis C virus core antibodies correlate with hepatitis C recurrence in liver graft recipients. (1996) (5)
- Are statins a remedy for all seasons? (2015) (5)
- [436] THE HEPATITIS C VIRUS CORE PROTEIN OF GENOTYPES 3a AND 1b DOWN-REGULATES INSULIN RECEPTOR SUBSTRATE 1 VIA GENOTYPE-SPECIFIC MECHANISMS (2007) (5)
- Extrahepatic manifestations of HCV. (2015) (5)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study (2010) (5)
- Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. (2010) (5)
- The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012. (2015) (5)
- 192 Early viral kinetics prediction of sustained virological response after 1 or 4 weeks of PEG-interferon-ALFA-2A and ribavirin therapy (Ditto-HCV project) (2003) (5)
- ABO incompatible kidney transplantation from an anti‐hepatitis C virus antibody‐positive RNA‐negative donor into an anti‐hepatitis C virus antibody‐negative recipient (2015) (5)
- Curbing hepatitis C virus spread in Egypt. (2014) (5)
- Detection of hepatitis C virus RNA by in situ hybridization: a critical appraisal (1994) (4)
- Trends in hepatitis C-related mortality in Switzerland (2017) (4)
- Hepatocellular carcinoma: pathogenetic implications of the hepatitis delta virus. (1993) (4)
- [Hepatocellular carcinoma : updated management guidelines]. (2018) (4)
- [Blood coagulation parameters in insulin-dependent diabetic children at onset of the disease and after 3 months]. (1989) (4)
- Statins may protect against hepatocellular carcinoma development in patients infected with hepatitis C virus, but what are the mechanisms? (2013) (4)
- Management of side effects of interferon alfa and ribavirin-based treatment of chronic hepatitis C (2005) (4)
- Alpha interferon therapy of chronic delta hepatitis: a pilot study. (1991) (4)
- Expression of the c‐myc protooncogene product in cells infected with the hepatitis delta virus (1994) (4)
- Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. (2021) (4)
- Tolerogenic properties of liver macrophages in non‐alcoholic steatohepatitis (2019) (4)
- Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over. (2017) (4)
- Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C (2013) (4)
- Pathobiology of hepatitis delta virus infection at the cell level. (1993) (4)
- [Hepatitis C and insulin resistance]. (2008) (4)
- Extrahepatic manifestations in hepatitis C virus infection (2016) (4)
- 1152IMPACT OF GENETIC CONCENTRATIVE NUCLEOSIDE TRANSPORTER VARIANTS ON PEG-INTERFERON/RIBAVIRIN THERAPY RESPONSE AND RIBAVIRIN SERUM LEVELS IN HEPATITIS C PATIENTS (2012) (3)
- 1401 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES VARIANTS ASSOCIATED WITH LIVER FIBROSIS PROGRESSION IN HCV-INFECTED PATIENTS (2012) (3)
- Clinical Practice Guidelines : Management of hepatitis C virus infection European Association for the Study of the Liver ⇑ (2013) (3)
- All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS) (2020) (3)
- Clinical significance of the antibody to the putative core protein of hepatitis C virus in patients with chronic liver disease. (2008) (3)
- Treatment of chronic hepatitis C. (2009) (3)
- In situ hybridizaiton in Viral hepatitis (2008) (3)
- Characterization of hepatitis delta antigen gene of a highly pathogenic strain of hepatitis delta virus. (1991) (3)
- P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS (2014) (3)
- P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather (2015) (3)
- Handbook of Hepatitis C (2016) (3)
- Overt and latent HBV infection. (1983) (3)
- Safe switch to beta-interferon treatment of chronic hepatitis C after alpha-interferon-induced autoimmune thrombocytopenia. (1996) (3)
- 1361 IL28B POLYMORPHISMS LINKED TO POOR RESPONSE TO TREATMENT ARE ASSOCIATED WITH LOW NECROINFLAMMATORY ACTIVITY AND SLOW FIBROSIS PROGRESSION IN HCV GENOTYPE NON-1-INFECTED PATIENTS (2011) (3)
- Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders (2018) (3)
- Ip-10 Is Associated With Il28b Variation And Predicts The First Phase Decline Of Hcv Rna And Outcome Of Therapy In Chronic Hepatitis C (2010) (3)
- 134 In vitro antiviral activity of SCH6, a novel inhibitor of the hepatitis C virus NS3 serine protease (2003) (3)
- In vitro antiviral activity of SCH6, a novel inhibitor of the hepatitis C virus NS3 serine protease (2003) (3)
- BRIP 1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV-or HBV-related liver disease (2019) (3)
- Steatosis in chronic hepatitis C: friend or foe? (2008) (3)
- In situ detection of HCV : an overview. (1999) (3)
- [Typology of defunctioning colostomy and state of art in the treatment of bowel emergencies]. (2005) (3)
- PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis (2019) (3)
- P1285 the Disease Burden of Chronic Hepatitis C Virus (Hcv) Infection in Switzerland (2014) (2)
- Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study (2019) (2)
- [Therapy of chronic hepatitis B]. (2006) (2)
- Sequence homology between HDV RNA and 7SL RNA: implications for pathogenesis. (1991) (2)
- Full-genome sequence analysis of clinically representative hepatitis C virus isolates (2000) (2)
- [Reactivation of hepatitis B associated with immunosuppression]. (2013) (2)
- Hepatitis C virus genotype 1 associated with massive steatosis of the liver and hypo-beta-lipoproteinemia. (2004) (2)
- Preoperative parenteral nutritional support in gastric cancer. (1990) (2)
- Response prediction in chronic hepatitis C by assessment of IP-10 and IL 28 B-related single nucleotide polymorphisms LAGGING (2017) (2)
- Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection (2018) (2)
- P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE (2014) (2)
- 535 Is connective tissue growth factor (CTGF), the missing link between steatosis, insulin resistance and fibrosis in patients with chronic hepatitis C? (2006) (2)
- 420 INTERLEUKIN-28B POLYMORPHISMS, IP-10 AND VIRAL LOAD PREDICT VIROLOGICAL RESPONSE TO THERAPY IN CHRONIC HEPATITIS C UNDER REAL-LIFE CONDITIONS (2011) (2)
- Factors influencing the natural course of HDV hepatitis. (1991) (2)
- [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C]. (2015) (2)
- Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein. (2006) (2)
- A significant effect of the killer cell immunoglobulin‐like receptor ligand human leucocyte antigen‐C on fibrosis progression in chronic C hepatitis with or without liver transplantation (2016) (2)
- Delta infection among haemophiliacs. (1983) (2)
- Update : Hepatitis C Facts and fictions of HCV and comorbidities : Steatosis , diabetes mellitus , and cardiovascular diseases (2014) (2)
- 27. Structure and Molecular Virology (2013) (2)
- 810 DOWNREGULATION OF PTEN AND IRS1 BY HCV 3A CORE PROTEIN TRIGGERS STEATOSIS IN HEPATOCYTES (2011) (2)
- Book Review Fatty Liver Disease: NASH and Related Disorders Edited by Geoffrey C. Farrell, Jacob George, Pauline de la M. Hall, and Arthur J. McCullough. 319 pp., illustrated. Malden, Mass., Blackwell, 2005. $125. 1-405-11292-1 (2005) (2)
- [Detecting hepatitis C virus RNA by in situ hybridization: a critical analysis]. (1997) (2)
- [Removal of foreign bodies from the upper airways and the bronchial tree of small children]. (1980) (2)
- Effect of hepatitis B virus on steatosis in hepatitis C virus co‐infected subjects: A multi‐centre study and systematic review (2018) (2)
- 1419 IL28B RNA EXPRESSION DEPENDS ON A NOVEL TT/-G POLYMORPHISM ASSOCIATED WITH IMPROVED HCV CLEARANCE PREDICTION (2013) (1)
- Hepatitis C virus (2014) (1)
- 773 HEPATITIS C VIRUS AND LIPID DROPLETS: ROLE OF SEIPIN IN LIPID DROPLET MATURATION AND VIRAL LIFE CYCLE (2011) (1)
- P833 QUERCETIN MODULATES LIPIDS DROPLETS IN Huh7 CELLS BEARING PNPLA3 GENOTYPE GG (2014) (1)
- The tragedy of (unpublished) errors (2006) (1)
- 1357 A LARGE-SCALE GENETIC VALIDATION STUDY COUPLED WITH IN-VITRO ANALYSES REVEAL A ROLE OF VITAMIN D-SIGNALING IN THE PATHOGENESIS AND TREATMENT OF CHRONIC HEPATITIS C (2011) (1)
- [Cell transplantation: current treatments and future prospects]. (2014) (1)
- Steatosis in chronic hepatitis C. Authors' reply (2006) (1)
- [What's new in the treatment of hepatitis B infection?]. (2009) (1)
- Transitory ischemic attack and acute hepatitis C. (2000) (1)
- Preoperative parenteral nutrition in malnourished surgical patients: a prospective randomized study (1990) (1)
- 772 ACTIVE INTRAVENOUS DRUG USE DURING CHRONIC HEPATITIS C THERAPY DOES NOT REDUCE SUSTAINED VIROLOGIC RESPONSE RATES IN ADHERENT PATIENTS (2008) (1)
- [Cervical and sternotomic approaches to the non-neoplastic thymus in myasthenia. Comparison based on long-term results]. (1985) (1)
- P.1.111: POST LOAD INSULIN RESISTANCE IS NOT A PREDICTOR OF SUSTAINED VIROLOGIC RESPONSE IN CHRONIC HEPATITIS C PATIENTS RECEIVING PEG-INTERFERON PLUS RIBAVIRIN (2011) (1)
- Hepatitis B and D (2011) (1)
- The 4,977–base pair common deletion of mitochondrial DNA is not associated with steatosis in chronic hepatitis C patients (2002) (1)
- 936 LOW SERUM FERRITIN IS AN INDEPENDENT PREDICTOR OF HEPATITIS C VIRUS (HCV) CLEARANCE: A POPULATION-BASED STUDY (2012) (1)
- Severe liver injury possibly due to verapamil (1986) (1)
- [Hepatitis B: new guidelines of disease management]. (2017) (1)
- In vitro antiviral activity of SCH 446211 ( SCH 6 ) , a novel inhibitor of the hepatitis C virus NS 3 serine protease (2006) (1)
- Watchful monitoring for hepatitis B reactivation after intensive chemotherapy. (1999) (1)
- Eczema‐like lesions and disruption of therapy in patients treated with interferon‐alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment: reply from authors (2004) (1)
- The intrahepatic T helper cytokine profile does not predict the response to alpha-interferon in chronic hepatitis C. (2001) (1)
- 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project) (2004) (1)
- Hepatitis G Virus Infection Among Liver Graft Recipients: Anatomoclinical Correlations (1998) (1)
- Leiomyoma of the esophagus. (A case report). (1997) (0)
- 240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldaprevir Phase III Trials (2014) (0)
- O322: HCV and lymphoma (2014) (0)
- [Chronic hepatitis C: current treatment and perspectives]. (2011) (0)
- Book Review Virus Hunter: Thirty years of battling hot viruses around the world By C.J. Peters, with Mark Olshaker. 323 pp., illustrated. New York, Anchor Books, 1997. $23.95. 0-385-48557-3 (1997) (0)
- 495 Steatosis and fibrosis in chronic hepatitis C: Relative role of lipid peroxidation, leptinemia and insulin resistance (2004) (0)
- SAT-166-Hepatitis C virus-based experimental models in the study of liver-driven altered glucose homeostasis (2019) (0)
- Nonradioisotopic in situ hybridization for HDV RNA. (2004) (0)
- HBV replication influences the course of chronic hepatitis D (1991) (0)
- Accumulation of a cellular protein bearing c-myc-like antigenicity in hepatic and non-hepatic delta antigen expressing cells. (1993) (0)
- Hepatitis C Virus Core Protein of Genotype 3A Downregulates PTEN Expression in Hepatocytes through Micrornas-Dependent Mechanisms (2016) (0)
- New Diagnostic Techniques: Hepatitis B Virus-DNA in Serum and Liver (1986) (0)
- Update in Drug Development for Chronic HBV/HDV Infection (2019) (0)
- A letter of solidarity during the COVID‐19 pandemic (2020) (0)
- P1174 THE NOVEL ss469415590 POLYMORPHISM PREDICTS RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS TYPE 1 INFECTION (2014) (0)
- O321: HCV and insulin resistance (2014) (0)
- [New aspect in the treatment of chronic hepatis B]. (2005) (0)
- Hepatitis C virus-related oral lichen planus: geographical heterogeneity is linked to HLA-DR6 allele (2002) (0)
- Immunological and antiviral effects of ribavirin in recurrent hepatitis C after liver transplantation (2000) (0)
- Genotype 3 and circulating SCCA-IgM are independently associated with histological features of NASH in HCV infected patients (2014) (0)
- [Supportive parenteral nutrition in surgical patients at risk. Prognostic findings in 80 cases]. (1987) (0)
- 1143 INHIBITION OF THE INSULIN-MEDIATED AS160 ACTIVATION IS AN IMPORTANT EVENT LEADING TO INCREASED HCV EGRESS (2013) (0)
- [Our friend...coffee]. (2007) (0)
- Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis (2019) (0)
- The heavy burden of hepatitis D in Uzbekistan (2019) (0)
- [Efficacy of new therapies]. (2020) (0)
- P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES (2014) (0)
- All-cause mortality and causes of death in the Swiss Hepatitis C Cohort Study (2019) (0)
- Hepatitis C virus :clinical significance of anti-HCV and HCV-RNA and characterization of an Italian isolate (1989) (0)
- The Role of Chimpanzees in Hepatitis D Research (1994) (0)
- Elimination of hepatitis C in two different Swiss regions – A model-based microelimination scenario (2018) (0)
- Humanherpes virus-6 increases HIV-1expression in co-infected T cells vianuclear factors binding tothe HIV-1enhancer (1989) (0)
- Nonalcoholic fatty liver disease burden (2019) (0)
- The core protein of HCV genotype 3A, 3H and 1B induces lipid accumulation in a hepatoma cell line (2003) (0)
- Hepatitis C transmission: current issues (Part One) (2005) (0)
- [The challenges of HIV-HCV co-infection]. (2012) (0)
- Ovarian adenocarcinoma in teenagers and young adults: A clinical challenge (2007) (0)
- Presacral epidermoid cyst (2006) (0)
- Hepatitis C virus-induced MiR-21 activation triggers steatosis and promotes hepatitis C virus life cycle (2017) (0)
- Vaccination against hepatitis B and C: the state of the art (2005) (0)
- The 4977-BP common deletion of mitochondrial DNA is not associated with steatosis in chronic hepatitis C patients (2001) (0)
- Diagnosis of hepatitis delta virus infection. (1995) (0)
- woodchucks.chronic WHV carrier of hepatitis virus (WHV) nucleic acids in tissues Hepatitis delta virus (HDV) and woodchuck (2013) (0)
- OP44 Cost-Effectiveness Of Hepatitis C Virus Screening In Swiss Prisons Using Rapid Tests (2017) (0)
- P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER (2015) (0)
- Transitory ischemic attack and acute hepatitis C (2000) (0)
- HCV induced-miR-21 activation triggers lipid accumulation and promotes viral replication (2018) (0)
- P196 INVESTIGATION OF HEPATITIS C VIRUS ADAPTATION TO HOST GENETIC POLYMORPHISMS (2014) (0)
- [Plasmatic ACTH levels in acromegaly]. (1972) (0)
- [Dermatitis associated with the treatment of chronic hepatitis C]. (2005) (0)
- T-34 Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions (2011) (0)
- 885 INTRAHEPATIC MRNA LEVELS OF THE SUPPRESSORS OF CYTOKINE SIGNALLING 1 AND 3 ARE ASSOCIATED WITH CIRRHOSIS BUT NOT WITH TREATMENT RESPONSE IN CHRONIC HEPATITIS C (2012) (0)
- Retraction for Waris et al., “Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress” (2020) (0)
- Diagnostic tools from molecular biology. (2008) (0)
- Real-time PCR quantitation of 5′ and 3′ untranslated regions of hepatitis C virus RNA in liver tissue (2003) (0)
- Medical decision making under uncertainty in adult patients (pts) with multiple primary cancer (MPC). (2006) (0)
- [Buyers' club : an alternative for access to treatment ?] (2020) (0)
- 865 THE PROTEIN PHOSPHATASE ACTIVITY OF PTEN CONTROLS THE CHOLESTEROL METABOLISM IN HEPATOCYTES AND PREVENTS HCV SECRETION BY INFECTED CELLS (2012) (0)
- Immunohistochemical detection of hepatitis delta antigen. (2004) (0)
- Steatosis affects chronic hepatitis C progression in a genotype-dependent way (2003) (0)
- Défis de la co-infection par le virus de l’hépatite C et le VIH (2012) (0)
- [Complications in chronic HBV infection]. (1998) (0)
- 546 Early HCV-RNA decline in peripheral blood mononuclear cells predicts SVR versus relapse in chronic hepatitis C patients treated with pegylated interferon-α plus ribavirin (2006) (0)
- 795 HEPATITIS C VIRUS AND THE METABOLIC SYNDROME: CROSS-TALK BETWEEN INFECTED AND UNINFECTED CELLS (2011) (0)
- Malnutrition, stress and immunodepression: their interrelationship with fungal infections (2008) (0)
- Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review (0)
- Influence of geographical origin on access to therapy and therapy outcomes in hepatitis C virus-infected persons: the Swiss Hepatitis C Cohort Study (2018) (0)
- [Cefotetan and intra-abdominal infections]. (1987) (0)
- The HCV particle and its life cycle (2016) (0)
- Immunology and Liver Disease / Liver and Metabolic Syndrome: Immunology and Liver Disease Falk Workshop 2009, Hannover, October 2009 / Liver and Metabolic Syndrome Falk Symposium 171, Hannover, October 2009 (2010) (0)
- Management of HCV Infection (2016) (0)
- [Extra-hepatic morbidity and mortality related to hepatitis C virus infection]. (2014) (0)
- Hepatitis C infection drugs pricing : evolution over time (2016) (0)
- SF-36 quality of life questionaire evaluation in a large cohort of women with breast cancer treated with hormonotherapy (2007) (0)
- Molecular state of hdv and whv nucleic acids in tissues of hdv infected chronic whv carrier woodchucks (1988) (0)
- [Technical aspects of neorectum: restorative proctocolectomy]. (1994) (0)
- Hepatitis A virus: still a hot topic? (2005) (0)
- Hepatitis C Virus and Insulin Signaling (2010) (0)
- Hepatitis C virus and gastric mucosa-associated lymphoid tissue: has proteus reached the stomach? (2004) (0)
- SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT (2014) (0)
- HCV-induced end-stage liver disease is the leading indication for liver transplantation in most western countries (0)
- In situ hybridization and the detection and localization of HCV RNA. (1999) (0)
- O111: Epidemiology: risk of transmission in various regions of the world and prevention of routes of transmission (2013) (0)
- Detection of 5′-to-3′ transcription gradient in hepatitis C virus-infected liver tissue (2003) (0)
- PDG110 A BUYERS' CLUB TO IMPROVE ACCESS TO HEPATITIS C AND HIV TREATMENT FOR VULNERABLE POPULATIONS (2019) (0)
- Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies (2014) (0)
- THU-203-Hepatitis D infection and risk of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies (2019) (0)
- [Immediate and remote problems following total pancreatectomy]. (1987) (0)
- [New treatments for hepatitis C, which targets, what timeline?]. (2011) (0)
- P837 GENOTYPE 3 AND CIRCULATING SCCA-IgM ARE INDEPENDENTLY ASSOCIATED WITH HISTOLOGICAL FEATURES OF NASH IN HCV INFECTED PATIENTS (2014) (0)
- [NASH: new terminology and what else is new in 2020]. (2020) (0)
- Significance of interferon resistance developing in chronic hepatitis C during continuous or pulse interferon treatment (1993) (0)
- Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma". (2020) (0)
- P660 THE EFFECT OH HEPATITIS B VIRUS INFECTION ON STEATOSIS IN HEPATITIS C VIRUS COINFECTED PATIENTS: THE BOSTIC STUDY (2014) (0)
- Titration of intrahepatic (−) HCV RNA by strand-specific RT-PCR in chronic hepatitis C: morphological and clinical correlations (1998) (0)
- Book Review Chronic Viral Hepatitis: Diagnosis and Therapeutics Edited by Raymond S. Koff and George Y. Wu. 339 pp. Totowa, N.J., Humana Press, 2001. $99.50. 0-89603-880-7 (2002) (0)
- Off-label prescriptions in cancer: Who should pay for them? (2011) (0)
- Steatosis does not affect the result of antiviral treatment in HCV genotype 3 infected patients (2005) (0)
- IDDF2019-ABS-0212 Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis (2019) (0)
- [Hepatitis D: forgotten but not gone]. (2010) (0)
- Treatment of chronic hepatitis B: an update (2005) (0)
- Editor's Note (2017) (0)
- HEPATITIS C VIRUS AND SPECIFIC CARDIOVASCULAR DISEASE MANIFESTATIONS Hepatitis C Virus Infection and Carotid Atherosclerosis (2017) (0)
- Treatment of Genotype 1 Hepatitis C patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Austria and Switzerland (2013) (0)
- Metabolic Factors and Steatosis in Patients with Hepatitis B and C (2013) (0)
- [Is there hope for hepatitis delta ?] (2016) (0)
- Hepatitis C virus and type 2 diabetes: epidemiological association and clinical interactions (2012) (0)
- Fat and viral liver disease (2009) (0)
- 829 HEPATITIS C VIRUS AND LIPID DROPLETS: LIPIDOMIC PROFILING OF HCV CORE PROTEIN-EXPRESSING HEPATOMA CELLS (2012) (0)
- Antibiotic treatment of abdominal infections. (1987) (0)
- 417 EFFECT OF ANTIVIRAL THERAPY ON THE CIRCULATING LEVELS OF CYTOKERATIN-18 FRAGMENTS IN CHRONIC HEPATITIS C (2009) (0)
- In situ versus bench resection of liver allografts before orthotopic liver transplantation. (1989) (0)
- 1058 Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis (2019) (0)
- Hepatitis C virus and metabolism. 2nd edition (2009) (0)
- P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS (2014) (0)
- [Management of hepatitis B]. (2004) (0)
- [Pituitary corticotropin function in hypertonic obesity "with rose striae"]. (1970) (0)
- Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions (2011) (0)
- Impact of Soluble CD 26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (0)
- Mo1393 - Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Psychiatric Disorders (2018) (0)
- Immunobiology of Hepatitis B and D Virus Infections (1994) (0)
- T-28 Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study (2012) (0)
- Difficult-to-treat patients with chronic hepatitis C (Part One) (2005) (0)
- 1140 HEPATITIS C VIRUS AND LIPID DROPLETS: ROLE OF ADIPOSE DIFFERENTIATION-RELATED PROTEIN IN LIPID DROPLET MORPHOLOGY AND VIRAL LIFE CYCLE (2013) (0)
- Age Above 60 Years Is Not a Negative Predictive Factor For Combined Antiviral Therapy With Pegylated Interferon Alpha and Ribavirin in Hepatitis C Patients (2012) (0)
- Does the hepatitis C virus interfere with the apoptosis cascade in vivo (2000) (0)
- [Tissue genes: the application of hybridization in situ in hepatology]. (1995) (0)
- Hepatitis C and metabolism (2005) (0)
- New antivirals in hepatitis C (2005) (0)
- Etiology and epidemiology of prescriptive errors in the practice of clinical oncology (2008) (0)
- [The children from Zanzibar, hepcidin and iron]. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Francesco Negro?
Francesco Negro is affiliated with the following schools:
